Sanfilippo A is mucopolysaccharidosis type IIIA: deficiency of the enzyme that degrades heparan sulphate, which then accumulates in the central nervous system. Children develop close to normally and then lose what they gained, speech and sleep first, then cognition and motor function. Until this approval, everything on offer was supportive. A first approved therapy in a neurodegenerative lysosomal disorder is the kind of event that redefines what the rest of the pathway is for.
It also relocates the problem rather than closing it. Damage in Sanfilippo A is neurological and cumulative, so the value of any disease-modifying treatment depends almost entirely on arriving before the regression it is meant to prevent, and these children are usually diagnosed after it has started. An approval therefore raises the stakes on everything upstream of it: screening, phenotype capture, time from first concern to molecular answer. Read it against item 07 below, which is the largest account yet of what genomic newborn screening can and cannot deliver.
Pooled across trials rather than read one press release at a time. Functional gains in this field have been smaller than the expectations set around them and the safety record is not empty, so a meta-analysis is exactly what clinicians and families need before the next conversation about whether to enrol.
The genes are present and intact on the maternal chromosome; they are switched off. Unsilencing them sidesteps delivery of a gene altogether, the same logic as the X reactivation work in Rett covered in the last edition. The challenges half of the title is where the substance is, specificity above all.
Correction of the sickle mutation itself, rather than reactivating fetal haemoglobin to compensate for it. The development account is the useful part: editing efficiency, manufacturing and the release criteria a product like this has to meet, all of which bear on whether it could ever run outside a handful of centres.
India has no dedicated statutory protection against the use of genetic information in insurance or employment. This works through what the constitutional guarantees of equality and privacy could be made to do in that gap, and what remains unprotected even if they are. The clinical stake is direct: where families expect a result to be used against them, they decline testing, and the undiagnosed stay undiagnosed.
Every laboratory classifying variants depends on data other laboratories have deposited, and a large share deposit nothing in return. This sets out the professional expectation to share, and the consent and privacy conditions under which it can be done. Worth reading directly after item 05, because sharing obligations and discrimination protections are the same argument approached from opposite ends.
Pooled experience across programmes in several countries, and the largest account so far of sequencing newborns outside a research question. The hard parts are gene list design, what counts as actionable in an infant with no symptoms, how often a finding turns out not to matter, and whether families were served or alarmed by knowing. This is where the feature above eventually has to lead.
The comparison that decides whether microarray stays in the pathway. If sequencing-based copy number calling holds up against array across a cohort this size, running both tests becomes difficult to defend on cost or on turnaround, and the first-tier decision changes accordingly.
A normal karyotype in recurrent pregnancy loss closes the investigation without explaining anything. Optical genome mapping resolves balanced rearrangements that karyotype cannot see, which turns unexplained loss into a quantified recurrence risk with reproductive options attached to it.
Turnaround measured in hours changes what a genetic result is for: it stops being an explanation offered afterwards and becomes an input to the decision being made now, in intensive care. Read it for the line between what has been demonstrated in practice and what is still being projected from it.
Surveillance schedules in PTEN hamartoma tumour syndrome rest on penetrance and age-of-onset estimates drawn from cohorts, and those estimates shift as testing reaches people ascertained for milder features. Cohort descriptions are how the recommendations eventually get corrected.
Citrin deficiency is hard to follow between episodes, and dietary management proceeds largely on symptoms. A circulating marker that tracks the underlying metabolic disturbance would give something to measure, which matters as much for trial endpoints as for clinic.
What happens after the positive screen, surveyed nationally: who gets treated, at what enzyme threshold, and for how long they are followed. Partial deficiency is where practice diverges most, and a screening programme is judged on what follows detection rather than on detection itself.
A stroke in a child with no vascular explanation should raise a metabolic question, and stroke-like episodes in metabolic disease do not always behave like stroke on imaging. The value here is the pattern recognition, since the treatable causes are the ones most easily missed in an acute presentation.
